The Food and Drug Administration and CancerLinQ — the American Society of Clinical Oncology's big data effort — teamed up June 1 to research new cancer therapies.
CancerLinQ and FDA researchers will use the analytics platform CancerLinQ Discovery to analyze de-identified patient care data from participating oncology practices. The CancerLinQ network currently includes almost 90 oncology practices.
"This collaboration addresses one of oncology's central challenges — to quickly learn about the real-world impact of cancer therapies once a drug is approved," said Clifford A. Hudis, MD, CEO of ASCO and chairman of CancerLinQ's board of governors.
The organizations hope the project will improve understanding of cancer patients' real-world experience and inform clinical use of newly approved therapies. They also aim to inform future FDA regulatory strategies and accelerate the development of new cancer therapies.
More articles on health IT:
OCR portal: Top 10 data breaches affecting largest number of individuals
5 study insights into patient safety events when EHRs go down
FCC CIO leaves post to head new innovation office: 4 things to know